Senores Pharmaceuticals Limited — PPTs, 15-12-2025: Investor Presentation

Senores Pharma is making a major strategic move by acquiring Apnar Pharma, which comes with a US-FDA, MHRA, & Health Canada-approved manufacturing facility. This deal, valued at approx. Rs. 91 Cr (Rs. 15 Cr cash, Rs. 76 Cr debt taken over), significantly expands Senores' market access to the UK & Canada while strengthening its US presence.

The acquisition also includes 5 ANDAs, with 3 ready for immediate commercialization, targeting a ~$722 Mn market opportunity. This backward integration will improve margins and supply reliability. Management sees this as a key growth accelerator, expecting better operating leverage and margin expansion by shifting some US product manufacturing to India. Senores plans to expand its product portfolio, scale CDMO/CMO, and grow branded generics. Big boost for long-term growth!